Value of Cardiopulmonary Exercise Testing in the Prognosis Assessment of Chronic Obstructive Pulmonary Disease Patients: A Retrospective, Multicentre Cohort Study.

All-cause mortality Cardiopulmonary exercise testing Chronic obstructive pulmonary disease Lung function Prognosis

Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
2022
Historique:
received: 20 05 2021
accepted: 07 09 2021
pubmed: 22 11 2021
medline: 6 4 2022
entrez: 21 11 2021
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases associated with high mortality. Previous studies suggested a prognostic role for peak oxygen uptake (VO2peak) assessed during cardiopulmonary exercise testing (CPET) in patients with COPD. However, most of these studies had small sample sizes or short follow-up periods, and despite their relevance, CPET parameters are not included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) tool for assessment of severity. We therefore aimed to assess the prognostic value of CPET parameters in a large cohort of outpatients with COPD. In this retrospective, multicentre cohort study, medical records of patients with COPD who underwent CPET during 2004-2017 were reviewed and demographics, smoking habits, GOLD grade and category, exacerbation frequency, dyspnoea score, lung function measurements, and CPET parameters were documented. Relationships with survival were evaluated using Kaplan-Meier analysis, Cox regression, and receiver operating characteristic (ROC) curves. Of a total of 347 patients, 312 patients were included. Five-year and 10-year survival probability was 75% and 57%, respectively. VO2peak significantly predicted survival (hazard ratio: 0.886 [95% confidence interval: 0.830; 0.946]). The optimal VO2peak threshold for discrimination of 5-year survival was 14.6 mL/kg/min (area under ROC curve: 0.713). Five-year survival in patients with VO2peak <14.6 mL/kg/min versus ≥ 14.6 mL/kg/min was 60% versus 86% in GOLD categories A/B and 64% versus 90% in GOLD categories C/D. We confirm that VO2peak is a highly significant predictor of survival in COPD patients and recommend the incorporation of VO2peak into the assessment of COPD severity.

Identifiants

pubmed: 34802005
pii: 000519750
doi: 10.1159/000519750
pmc: PMC9153340
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-366

Informations de copyright

© 2021 The Author(s). Published by S. Karger AG, Basel.

Références

Tuberk Toraks. 2019 Jun;67(2):83-91
pubmed: 31414638
Respiration. 2013;86(5):407-13
pubmed: 23735701
Intern Med. 2005 Jan;44(1):20-5
pubmed: 15704658
Pneumologie. 2006 Sep;60(9):576-84
pubmed: 17006795
Eur Respir J. 2013 Aug;42(2):323-32
pubmed: 23222874
Eur Respir Rev. 2016 Sep;25(141):333-47
pubmed: 27581832
Chest. 2002 May;121(5):1434-40
pubmed: 12006425
N Engl J Med. 2019 Sep 26;381(13):1257-1266
pubmed: 31553837
Eur Respir J. 1993 Mar;6 Suppl 16:41-52
pubmed: 24576916
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
COPD. 2019 Apr;16(2):174-181
pubmed: 31272243
Respiration. 2021;100(5):395-403
pubmed: 33657565
Pneumologie. 2012 Jul;66(7):402-7
pubmed: 22623039
Eur Heart J. 2011 Oct;32(19):2365-75
pubmed: 21875856
Respir Care. 2014 Feb;59(2):252-62
pubmed: 23821762
Lancet. 2009 Aug 29;374(9691):704-11
pubmed: 19716962
Pneumologie. 2013 Jan;67(1):58-63
pubmed: 23247595
Respiration. 2010;80(6):453-62
pubmed: 20224250
Rev Mal Respir. 2011 Mar;28(3):290-6
pubmed: 21482330
Eur Respir J. 2014 Dec;44(6):1521-37
pubmed: 25359358
COPD. 2016 Aug;13(4):416-24
pubmed: 27077955
Eur Respir Rev. 2013 Dec;22(130):454-75
pubmed: 24293462
Am J Respir Crit Care Med. 2003 Feb 15;167(4):544-9
pubmed: 12446268
Chest. 2007 Nov;132(5):1500-5
pubmed: 17925427
Eur Respir J. 2014 Nov;44(5):1199-209
pubmed: 25063247
Int J Chron Obstruct Pulmon Dis. 2011;6:521-6
pubmed: 22069363
Eur Respir J. 2008 Nov;32(5):1269-74
pubmed: 18579541
Respiration. 2014;88(4):307-14
pubmed: 25227115
Am J Respir Crit Care Med. 2007 Mar 1;175(5):458-63
pubmed: 17158282
Respiration. 2015;90(4):332-51
pubmed: 26352941
Chronic Obstr Pulm Dis. 2019 Nov;6(5):400-413
pubmed: 31710795
J Cardiopulm Rehabil Prev. 2016 Nov/Dec;36(6):454-459
pubmed: 27779551
Int J Chron Obstruct Pulmon Dis. 2021 Jun 01;16:1509-1517
pubmed: 34103908
Front Physiol. 2018 Oct 02;9:1293
pubmed: 30333757
Am J Respir Crit Care Med. 2009 Dec 15;180(12):1189-95
pubmed: 19797160
Eur J Cardiovasc Prev Rehabil. 2008 Dec;15(6):726-34
pubmed: 19050438
Clin Physiol Funct Imaging. 2003 Nov;23(6):324-31
pubmed: 14617262
Eur Respir J. 2015 Feb;45(2):377-87
pubmed: 25359345
Eur Respir J. 2008 Oct;32(4):962-9
pubmed: 18579551
Respiration. 2009;77(1):3-17
pubmed: 19145106

Auteurs

Ralf Ewert (R)

Internal Medicine B, Pneumology, University Hospital Greifswald, Greifswald, Germany.

Anne Obst (A)

Internal Medicine B, Pneumology, University Hospital Greifswald, Greifswald, Germany.

Andreas Mühle (A)

Teuchern Specialist Centre, Teuchern, Germany.

Michael Halank (M)

Internal Medicine, Pneumology, University Hospital Dresden, Dresden, Germany.

Jörg Winkler (J)

Medical Practice Leipzig, Leipzig, Germany.

Bernd Trümper (B)

Medical Practice Breathing & Sleep Erfurt, Erfurt, Germany.

Gerhard Hoheisel (G)

Medical Practice Leipzig, Leipzig, Germany.

Andreas Hoheisel (A)

Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.

Mark Wiersbitzky (M)

Medical Practice Anklam, Anklam, Germany.

Alexander Heine (A)

Internal Medicine B, Pneumology, University Hospital Greifswald, Greifswald, Germany.

Alexander Maiwald (A)

Internal Medicine B, Pneumology, University Hospital Greifswald, Greifswald, Germany.

Sven Gläser (S)

Internal Medicine B, Pneumology, University Hospital Greifswald, Greifswald, Germany.
Internal Medicine, Pneumology, Vivantes Hospital Berlin, Berlin, Germany.

Beate Stubbe (B)

Internal Medicine B, Pneumology, University Hospital Greifswald, Greifswald, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH